GlobalData on MSN20h
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
Pharma companies turn to AI to speed up drug development, but hit hurdles
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
Futurism on MSN14h
Doctors Have One Weird Trick to Tell When Their Colleagues Are On Ozempic
Doctors have begun noticing a trend: they all seem to get full before finishing dinner, and it's likely thanks to drugs like ...
STAT18h
Vertex pain pill dominates earnings call discussion
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Pharm Exec17h
The Teva Turnaround: Steering a Company Comeback
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...
Jim Cramer Backs Eli Lilly (LLY): Will Its Drug Pipeline Dominate Pharma?
We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...
National Signing Day: Where did Nashville area's top athletes in all sports sign?
National Signing Day for TSSAA football players is Wednesday, but college signees in other Tennessee high school sports have emerged since the early period for those sports. Here is a list of the ...